Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320757 | 0.95 | GABRA5 (0.60) | GABRA5HDAC4 | |
| SCHEMBL2317839 | 0.93 | GABRA5 (0.49) | GABRA5HDAC4 | |
| SCHEMBL2320601 | 0.93 | GABRA5 (0.57) | GABRA5 | |
| SCHEMBL2319476 | 0.91 | GABRA5 (0.51) | GABRA5 | |
| SCHEMBL2321175 | 0.89 | GABRA5 (0.54) | GABRA5HDAC4 | |
| SCHEMBL2319074 | 0.88 | GABRA5 (0.52) | GABRA5HDAC4 | |
| SCHEMBL2319340 | 0.88 | GABRA5 (0.61) | GABRA5HDAC4 | |
| SCHEMBL2318316 | 0.88 | GABRA5 (0.60) | GABRA5HDAC4 | |
| SCHEMBL2317390 | 0.86 | GABRA5 (0.59) | GABRA5 | |
| SCHEMBL2319661 | 0.85 | GABRA5 (0.44) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170873-B1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | claimed |
| US-7851469-B2 | Isoxazole-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | claimed |
| EP-2170873-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-04-07 | — | — | EP | claimed |
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-01 | — | — | US | claimed |
| WO-2009000662-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | WO | claimed |
| EP-2170873-B1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-7851469-B2 | Isoxazole-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2170873-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2009000662-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885HDAC4 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.